Title:NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents
Volume: 13
Issue: 1
Author(s): Spandana R. Kopalli , Tae-Bong Kang , Kwang-Ho Lee and Sushruta Koppula*
Affiliation:
- College of Biomedical and Health Sciences, Konkuk University, Chungju,Korea
Keywords:
Caspase, colitis, inflammasome, interleukin, MCC950, melanoma, sulphonyl urea.
Abstract: Background: Inflammasomes are recognized as key regulators in innate immunity from the
pathogenic to endogenous danger signals. Although controlled activation of inflammasome is highly
beneficial, dysregulation of inflammasome activation plays central role in various autoimmune, inflammatory
disorders and aid in promoting various forms of cancers in humans such as breast cancer,
fibrosarcoma, gastric carcinoma, and lung metastasis. NLRP3 inflammasome activation has been
emerged as a topic of interest and is under profound investigation for its involvement in multiple forms
of cancers.
Objective: This review emphasizes an overview of the recent patents on NLRP3 inflammasome activation
inhibitors with their relevant biological/pharmacological properties for the prevention and treatment
of inflammation-associated cancer disorders.
Methods: Data were obtained from online patent searchers such as World Intellectual Property Organization
(WIPO®), Free Patent Online (FPO), Espacenet® and Google Patents.
Results: Several NLRP3 inflammasome activation inhibitors were recently patented from naturally
derived and synthetic agents mainly by academic researchers. Most of the claimed patents have been
validated and confined to cell lines and animal models limiting their entry into clinical settings.
Conclusion: The vigorous effort to discover and develop agents to specifically inhibit NLRP3 inflammasome
activation, may pave the way to therapeutic intervention targeting inflammasome-regulated
pathways that are involved in the pathogenesis of various forms of cancer.
